Complete agreement on the currently approved AD drugs. lecanemab and donanemab both come with brain swelling/bleeding. blacarmasine has some advantages (taken orally, no reported brain swelling issues), but has some significant drawbacks (dizziness and confusion were major side effects). There's also some unresolved questions about dosing in their latest trial.